- Home
- CRL vs XOMAP Comparison
CRL vs XOMAP Comparison
Compare CRL & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRL
- XOMAP
- Stock Information
- Founded
- CRL 1947
- XOMAP N/A
- Country
- CRL United States
- XOMAP United States
- Employees
- CRL N/A
- XOMAP 13
- Industry
- CRL Biotechnology: Commercial Physical & Biological Resarch
- XOMAP Biotechnology: Pharmaceutical Preparations
- Sector
- CRL Health Care
- XOMAP Health Care
- Exchange
- CRL Nasdaq
- XOMAP Nasdaq
- Market Cap
- CRL N/A
- XOMAP N/A
- IPO Year
- CRL 2000
- XOMAP N/A
- Fundamental
- Price
- CRL $195.80
- XOMAP $25.78
- Analyst Decision
- CRL Hold
- XOMAP
- Analyst Count
- CRL 13
- XOMAP 0
- Target Price
- CRL $212.09
- XOMAP N/A
- AVG Volume (30 Days)
- CRL 851.5K
- XOMAP N/A
- Earning Date
- CRL 11-06-2024
- XOMAP N/A
- Dividend Yield
- CRL N/A
- XOMAP N/A
- EPS Growth
- CRL N/A
- XOMAP N/A
- EPS
- CRL 8.00
- XOMAP N/A
- Revenue
- CRL $4,060,916,000.00
- XOMAP N/A
- Revenue This Year
- CRL N/A
- XOMAP N/A
- Revenue Next Year
- CRL $1.21
- XOMAP N/A
- P/E Ratio
- CRL $24.44
- XOMAP N/A
- Revenue Growth
- CRL N/A
- XOMAP N/A
- 52 Week Low
- CRL $176.48
- XOMAP N/A
- 52 Week High
- CRL $275.00
- XOMAP N/A
- Technical
- Relative Strength Index (RSI)
- CRL 50.63
- XOMAP 46.03
- Support Level
- CRL $183.55
- XOMAP $25.69
- Resistance Level
- CRL $188.38
- XOMAP $25.98
- Average True Range (ATR)
- CRL 8.75
- XOMAP 0.13
- MACD
- CRL -1.02
- XOMAP -0.03
- Stochastic Oscillator
- CRL 30.90
- XOMAP 16.11
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.